Latest News Releases

PTA-Adhoc: Biofrontera AG: Biofrontera AG announces timing of the departure of the CEO

Public disclosure of inside information according to article 17 MAR

Leverkusen, Germany (pta012/02.12.2021/08:50) - Biofrontera AG (ISIN: DE0006046113) (the "Company") has announced on November 10, 2021, that Prof. Dr. Lübbert has resigned from his position as member of the Management Board effective at the end of May 2022 and that a mutually agreed resignation before end of May 2022 was intended.

The Supervisory Board and Prof. Dr. Lübbert have agreed today that Prof. Dr. Lübbert will leave the Management Board of Biofrontera AG and the management of the German subsidiaries as of December 13, 2021. However, he will continue to serve as Executive Chairman of Biofrontera Inc.

The Supervisory Board is currently considering the future composition of the Management Board of Biofrontera AG.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: Nasdaq

[ source: http://www.pressetext.com/news/20211202012 ]

Biofrontera AG – an attractive investment

We are experts in photodynamic therapy. With our innovative products and treatment methods, we make our contribution to skin health and at the same time create value for our investors.

Biofrontera is listed on the Frankfurt Stock Exchange (B8F) and on the NASDAQ Stock Exchange (BFRA) in New York.